Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | FRK | P42685 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22719294 | 0.91 | CYP46A1 (0.47) | CYP46A1ALDH1A1 | |
| SCHEMBL29453733 | 0.91 | CYP46A1 (0.47) | CYP46A1ALDH1A1 | |
| SCHEMBL22719256 | 0.81 | CYP46A1 (0.53) | CYP46A1ALDH1A1 | |
| SCHEMBL29453637 | 0.81 | CYP46A1 (0.53) | CYP46A1ALDH1A1 | |
| SCHEMBL22719285 | 0.79 | CYP46A1 (0.50) | CYP46A1ALDH1A1MAP4K4EGFRPRKACA | |
| SCHEMBL22719283 | 0.78 | CYP46A1 (0.65) | CYP46A1ALDH1A1 | |
| SCHEMBL22719464 | 0.78 | CYP46A1 (0.52) | CYP46A1ALDH1A1 | |
| SCHEMBL22719463 | 0.77 | CYP46A1 (0.48) | CYP46A1ALDH1A1 | |
| SCHEMBL22719351 | 0.74 | CYP46A1 (0.49) | CYP46A1ALDH1A1 | |
| SCHEMBL22719149 | 0.73 | CYP46A1 (0.61) | CYP46A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |